Behavioral study on the combination therapy of anti-dementia drug

2015 Fiscal Year Final Research Report

• Project/Area Number: 24730642
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Experimental psychology
• Research Institution: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
• Principal Investigator: Yanai Shuichi 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (60469070)
• Research Collaborator: Endo Shogo ; Arasaki Tomoko
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: 記憶・学習 / 老化 / 多剤併用療法 / シロスタゾール / ドネペジル

Outline of Final Research Achievements

In the present study, we revealed that the PDE3 inhibitor cilostazol improved the impaired learning and memory function in aged C57BL/6J mice and senescence-accelerated mouse prone 8 (SAMP8) to the same extent as young mice. Based on these findings, a clinical trial is now underway in Japan to gain approval for the use of cilostazol in treating mild cognitive impairment.
In addition, sub-effective dose of cilostazol and donepezil in combination enhances learning and memory function in aged C57BL/6J mice. These results suggest that the combination therapy comprising two or more drugs may offer a new pharmacological approach for treating cognitive disorders, as the combination therapy demonstrated to be an effective strategy for treating some types of diseases.

Free Research Field

行動科学